Pharmacological action

Active ingredient - verapamil hydrochloride. The drug is a derivative difenilalkilamina refers to a selective blocker  Packing finoptin
 calcium channel I-Class. It has antihypertensive, antiarrhythmic and antianginal effects.

Antianginal effect is caused as a direct effect on the myocardium, and the influence on the peripheral geodynamics. Blocking calcium influx into the cell, finoptinum reduces the transformation of the enclosed energy into mechanical action thus reducing myocardial contractility.

Finoptin significantly reduces atrioventricular conduction and increases the refractory period. When supraventricular arrhythmias has antiarrhythmic effect.


When taken orally finoptin, getting into the body is absorbed by 90%. Metabolism occurs in the liver "first pass". The main metabolite - norverapamil. The half-life, the occasional reception is - 2, 5-7, 5 hours, whereby further receptions 4, 5-12 hours. The drug is derived mainly kidneys, and from 9 to 16% through the intestines. Following intravenous administration, the half-life is 2-5 hours.

Indications finoptin

  • angina (stable without vasoconstriction, vasospastic);
  • sinus tachycardia;
  • supraventricular tachycardia;
  • hypertensive crisis;
  • atrial tachyarrhythmia;
  • Primary hypertension;
  • Atrial premature beats;
  • atrial flutter;
  • arterial hypertension;
  • hypertrophic obstructive cardiomyopathy.

Dosage finoptin and user acceptance

Internal method - an initial dose of 40-80 mg, 3 times a day. For prolonged forms finoptinum single dose must be increased, and the reception frequency is lowered.

Perhaps finoptin intravenous (bolus) - slowly, controlling blood pressure and heart rate of the patient. Patients with severe liver dysfunction finoptin daily dose should not exceed 120 mg. The maximum permissible dose for adult patients at intake - 480 mg per day.

Side effects finoptin

Cardio-vascular system: a pronounced reduction in blood pressure, tachycardia, bradycardia, exacerbation of congestive heart failure; rarely - myocardial infarction, angina, arrhythmia; With rapid intravenous - collapse, atrioventricular block III degree, asystole.

On the part of the central nervous system and peripheral nervous system, depression, fatigue, dizziness, fatigue, anxiety, fear, confusion, drowsiness, headache, extrapyramidal disorders (trembling hands, mask-like face, ataxia, shuffling gait, difficulty swallowing, stiffness of limbs ).

From the digestive system: increased appetite, constipation (rarely - diarrhea), nausea, gingival hyperplasia.

Other possible side effects finoptin: weight gain, rarely - gynecomastia, agranulocytosis, galactorrhea, hyperprolactinemia, arthritis, pulmonary edema, peripheral edema, asymptomatic thrombocytopenia.


  • pregnancy;
  • sinoatrial block;
  • lactation;
  • atrioventricular block II and III;
  • severe hypotension;
  • Hypersensitivity to finoptin.

Admission finoptin during pregnancy and lactation

During the period of lactation and  Tablets finoptin
 finoptin during pregnancy is contraindicated.


According to the instructions finoptin should be used with caution:

  • myocardial infarction with left ventricular failure;
  • in heart failure in a chronic form;
  • bradycardia;
  • when AVblokade - I degree;
  • hepatic failure;
  • with severe aortic stenosis;
  • in renal failure;
  • under light or moderate arterial hypotension;
  • elderly patients;
  • children and adolescents under 18 years.

Effects on ability to work requires concentration

After receiving finoptin possible symptoms of drowsiness and dizziness, which can adversely affect the concentration.

Drug interaction finoptin

Combining Finoptinas antihypertensive drugs such as vasodilators, ACE inhibitors, thiazides, leads to mutual reinforcement of the antihypertensive effect.

The simultaneous use of beta-blockers, agents for inhalation anesthesia, antiarrhythmic drugs, increase the risk of bradycardia, heart failure, hypotension. For parenteral administration finoptin patients receiving beta-blockers, there is a risk of asystole, and hypotension.

In combination with acetylsalicylic acid Finoptinas known cases increase in bleeding time. Simultaneous treatment with digoxin increases the concentration of digoxin in the blood plasma.

The combination with disopyramide may cause severe hypotension and collapse. The simultaneous use of diclofenac reduces the concentration of verapamil in plasma.

When receiving, patients with hypertension, finoptin with clonidine, there were cases of cardiac arrest.

Simultaneous treatment with phenobarbital or phenytoin may cause a reduction in the concentration of verapamil in the blood.

Combining finoptin with enflurane or etomidate may cause an increase in duration of the anesthesia.